Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Motorcycles | 1 | 2011 | 8 | 0.390 |
Why?
|
| Automobile Driving | 1 | 2011 | 32 | 0.380 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 117 | 0.370 |
Why?
|
| Virus Diseases | 1 | 2011 | 392 | 0.290 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 443 | 0.290 |
Why?
|
| Cross Infection | 1 | 2011 | 549 | 0.270 |
Why?
|
| Critical Illness | 1 | 2011 | 743 | 0.260 |
Why?
|
| Mastectomy | 2 | 2020 | 1547 | 0.210 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2015 | 224 | 0.200 |
Why?
|
| Hospitalization | 1 | 2011 | 2206 | 0.190 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1233 | 0.180 |
Why?
|
| Clostridium Infections | 2 | 2015 | 261 | 0.180 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 16184 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 323 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2020 | 703 | 0.130 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 337 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 916 | 0.130 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 1047 | 0.110 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 654 | 0.110 |
Why?
|
| Wound Infection | 1 | 2013 | 66 | 0.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 693 | 0.100 |
Why?
|
| Florida | 1 | 2011 | 116 | 0.100 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 98 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1318 | 0.090 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 1347 | 0.090 |
Why?
|
| Risk Factors | 5 | 2019 | 17838 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1457 | 0.080 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 177 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 2044 | 0.080 |
Why?
|
| Shock, Septic | 1 | 2011 | 186 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2627 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 13979 | 0.080 |
Why?
|
| Diarrhea | 1 | 2011 | 732 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2011 | 510 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 2648 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2017 | 3067 | 0.070 |
Why?
|
| Quality of Life | 1 | 2020 | 4725 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2011 | 742 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2011 | 1315 | 0.060 |
Why?
|
| Axilla | 2 | 2018 | 924 | 0.060 |
Why?
|
| Adult | 7 | 2020 | 81619 | 0.060 |
Why?
|
| Gene Expression | 1 | 2013 | 3683 | 0.060 |
Why?
|
| Comorbidity | 1 | 2011 | 2430 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2011 | 759 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2017 | 6838 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2020 | 39722 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 30937 | 0.050 |
Why?
|
| Aged | 6 | 2020 | 73178 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 5188 | 0.050 |
Why?
|
| Incidence | 1 | 2011 | 5846 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 15260 | 0.040 |
Why?
|
| Young Adult | 3 | 2017 | 22071 | 0.040 |
Why?
|
| Middle Aged | 6 | 2020 | 90072 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3973 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 5439 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 423 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2019 | 13354 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 22467 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14681 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2011 | 9436 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 4970 | 0.040 |
Why?
|
| Female | 7 | 2021 | 148642 | 0.040 |
Why?
|
| Survival Rate | 1 | 2011 | 12523 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 1093 | 0.040 |
Why?
|
| Humans | 9 | 2021 | 271144 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 851 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 698 | 0.030 |
Why?
|
| United States | 1 | 2011 | 15998 | 0.030 |
Why?
|
| Male | 3 | 2015 | 128590 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2347 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 1045 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4510 | 0.020 |
Why?
|
| Leukocytes | 1 | 2013 | 424 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2017 | 1934 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2043 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 6420 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 10256 | 0.020 |
Why?
|
| Brain Injuries | 1 | 2015 | 799 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6165 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 3868 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2490 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 2526 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4394 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10354 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 32621 | 0.010 |
Why?
|